Lichen planus pemphigoides with antibodies against the BP180 C-terminal domain induced by pembrolizumab in a melanoma patient

J Dermatol. 2021 Sep;48(9):e449-e451. doi: 10.1111/1346-8138.16006. Epub 2021 Jun 5.

Authors

Satoshi Yoshida¹, Ken Shiraishi¹, Kazuki Yatsuzuka¹, Hideki Mori², Hiroshi Koga³, Norito Ishii³, Koji Sayama¹

Affiliations

¹ Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
² Department of Plastic and Reconstructive surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
³ Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan.

PMID: 34089265
DOI: 10.1111/1346-8138.16006

No abstract available

Keywords: BP180 C-terminal domain; BP180NC16a; immunoblotting; lichen planus pemphigoides; pembrolizumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Lichen Planus* / chemically induced
Melanoma* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab